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Lipoproteins, circulating complexes of lipid-bound pro-
teins, play central roles in the transport and metabolism of 
lipids. They  support  energy metabolism,  cholesterol  and 
phospholipids  supply  to  cell membranes,  and  fat-soluble 
vitamin transport. Apolipoproteins are integral constitu-
ents that determine the physical properties and the meta-
bolic fate of lipoproteins, stabilizing their structure, 
shuttling  cholesterol  and  triglycerides  throughout  the 
body, acting as ligands for cell surface receptors, and regu-
lating  enzymatic  activities  (1).  For  example,  apoA-I  pro-
vides major structural support for HDL, activates LCAT, 
and acts as a ligand for HDL receptors, facilitating HDL-
cholesterol (HDL-C) efflux capacity (2). apoB, the major 
Abstract Proteins involved in lipoprotein metabolism can 
modulate cardiovascular health. While often measured to 
assess adult metabolic diseases, little is known about the 
proteomes of lipoproteins and their relation to metabolic 
dysregulation and underlying inflammation in undernour-
ished child populations. The objective of this population 
study was to globally characterize plasma proteins system-
ically associated with HDL, LDL, and triglycerides in 500 
Nepalese children. Abnormal lipid profiles characterized 
by elevated plasma triglycerides and low HDL-cholesterol 
(HDL-C) concentrations were common, especially in children 
with subclinical inflammation. Among 982 proteins ana-
lyzed, the relative abundance of 11, 12, and 52 plasma pro-
teins was correlated with LDL-cholesterol (r = 0.430.70), 
triglycerides (r = 0.390.53), and HDL-C (r = 0.490.79) 
concentrations, respectively. These proteins included apoli-
poproteins and numerous unexpected intracellular and ex-
tracellular matrix binding proteins, likely originating in 
hepatic and peripheral tissues. Relative abundance of two-
thirds of the HDL proteome varied with inflammation, with 
acute phase reactants higher by 440%, and proteins in-
volved in HDL biosynthesis, cholesterol efflux, vitamin 
transport, angiogenesis, and tissue repair lower by 320%. 
Untargeted plasma proteomics detects comprehensive sets of 
both known and novel lipoprotein-associated proteins likely 
reflecting systemic regulation of lipoprotein metabolism and 
vascular homeostasis.  Inflammation-altered distributions of 
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scaffold for LDL and a ligand for LDL receptors, plays an 
essential  role  in  the delivery of  cholesterol  to peripheral 
tissues (3). apoCs and apoE, highly enriched in VLDL and 
chylomicrons, deliver fatty acids to tissues for energy me-
tabolism  and  regulate  the  clearance  of  triglyceride-rich 
particles from the plasma (1). Except for apoB, other apo-
lipoproteins are exchangeable between different lipopro-
tein complexes, while the core structural apolipoproteins 
confer the unique properties of different classes of lipopro-
teins (4).
Over the past decade, a more complete, if complex, pic-




HDL proteome, in particular, includes proteins involved 
not  only  in  lipid  transport  and metabolism  but  also  in 
inflammation, the complement system, protease inhibi-
tors, and wound healing, elucidating broader roles in 
anti-inflammatory, anti-oxidative, immune-regulatory, and 
anti-apoptotic capacities (6). Although newly discovered 
cotransported members of lipoprotein assemblies are less 
abundant and more transient than apolipoproteins (8), 
these minor proteins are important for lipoprotein metab-
olism and function, serving to modulate the atherogenic or 
cardioprotective properties of lipoproteins (16). Beyond 
proteins  physically  carried  by  lipoproteins,  plasma pro-
teomics  can  identify  intracellular  or  extracellular matrix 
proteins  involved  either  directly  or  indirectly  in  lipopro-
tein production, secretion, clearance, and a wide range of 
metabolic actions (17), as lipoproteins constantly interact 
with cells in hepatic and peripheral tissues, including the 
immune system.
As proteins are important cargoes of lipoproteins, changes 
in the composition of proteins can modify the metabolism 
and function of  lipoproteins. For example,  inflammation 
and infections induce multiple alterations in lipid and lipo-
protein metabolism (18). Chronic inflammatory diseases 
and  infections  are  associated with  hypertriglyceridemia 
and low HDL-C, as well as atherosclerosis (19–22),  likely 
affecting the innate immune response, which protects a host 





tribution of HDL protein subpopulations, including en-
zymes  and  lipid  transfer  proteins,  compromising  HDL 
functions (23). Systemic analysis of inflammation-induced 




Compelling epidemiologic and clinical evidence sug-
gests that the metabolic risk factors for cardiovascular dis-
ease can be detected and observed to progress throughout 
childhood (24). However, the family of plasma proteomes 
of lipoproteins [e.g., direct or indirect correlates of HDL-C 
and LDL-cholesterol (LDL-C)] in childhood, especially in 
low-resource  societies  where  subclinical  inflammation  is 
common, has rarely been explored. In 2006–2008, we con-
















Study population and field assessments
Children in this proteomics study are a subset of a large child 
follow-up cohort in the southeastern plains district of Sarlahi, 
Nepal. Briefly, a community-based cluster-randomized controlled 





child demographic and anthropometric characteristics, educa-
tion, dietary and morbidity history in the past week, and house-
hold socioeconomic status during home visits. Phlebotomists 
visited households of children early in the morning and collected 
venous blood samples in 10 ml sodium heparin vacutainers to pre-
vent blood clots. Collected blood samples were transported on ice 
to the project’s field laboratory in Sarlahi where plasma samples 
were separated by centrifugation (1,720 g for 15 min). Plasma 
samples were used for lipid assessments and remaining plasma 
was aliquoted into cryovials that were stored and shipped in liquid 
nitrogen tanks to the Center for Human Nutrition laboratory at 
Johns  Hopkins  University  in  Baltimore,  MD  where  they  were 
stored at 80°C until thawed for biochemical assessments and/or 
proteomics analysis (25). Among 2,130 children who met inclu-
sion criteria of having available plasma samples and complete 
epidemiological data from the original maternal micronutrient 
supplementation  trial  and  follow-up  study,  samples  from  1,000 
children, balanced across the five original maternal intervention 
groups (n = 200 in each) were randomly selected for micronutri-
ent and inflammation status assessments (28). Of these, 50% of 
the  samples  (n  =  100  from  each maternal  intervention  group) 
were randomly selected for proteomics analysis (29). The original 
antenatal micronutrient supplementation trial was registered at 
ClinicalTrials.gov  as NCT00115271. Oral  informed  consent was 
obtained from the parents of eligible children during the child 
follow-up due  to high  illiteracy  in  the study population. Ethical 
approval for the original maternal trial and child follow-up study 
was obtained from the institutional review board at the Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD and 
the Nepal Health Research Council in Kathmandu, Nepal. All 
methods were carried out in accordance with the principles of the 
Declaration of Helsinki.
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metric methods. This instrument has been certified for clinical 
application by  the US Center  for Disease Control’s Lipid Stan-
dardization Program (Atlanta, GA). The instrument is also ro-
bust and thus has been used for point-of-care diagnostic testing 
of lipid levels in remote areas of rural Nepal. The detectable 
ranges for total cholesterol, HDL-C, and triglycerides were 100–
500, 15–100, and 45–650 mg/dl, respectively. Estimates of plasma 






tion. For example, in Nepal, AGP identified five times more chil-
dren  with  systemic  low-grade  inflammation  than  CRP  using 





The processes of immune-depletion of high abundant pro-
teins  and MS-based  proteomics  analysis  have  been  previously 
described  (29).  Plasma  specimens  were  depleted  of  six  high 








ferent isobaric tags for relative and absolute quantification 
(iTRAQ) reagents, which have reporter ions to be detected for 
relative quantification, and were incubated at room tempera-
ture for 2 h. All labeled samples were combined and 90 l of the 
combined peptide sample was dissolved in 4 ml of strong cation 
exchange  loading  buffer  [25%  v/v  acetonitrile  and  10  mK 
KH2PO4 (pH 2.8)]. The  sample was  fractionated  into 24  frac-
tions by strong cation exchange chromatography on an Agilent 
1200 capillary HPLC system using a PolySulfoethyl A column. 
Peptides were loaded on to a reverse-phase nanobore column 
and  eluted  using  a  2–50%  acetonitrile  and  0.1%  formic  acid 
gradient  for  110  min  at  300  nl/min.  Eluting  peptides  were 
sprayed  into  an  LTQ  Orbitrap  Velos  mass  spectrometer 
(Thermo Scientific) and  interfaced with a NanoAcquity ultra-
HPLC  (Waters).  Precursors  and  the  fragment  ions  were  ana-
lyzed at resolutions of 30,000 and 15,000, respectively. Spectra 
from  full  MS  scans  and  fragmented  MS/MS  scans  were  ex-












Standard cut-offs for low or high plasma lipid levels for chil-
dren were derived from the National Cholesterol Education Pro-
gram  Expert  Panel  on  Cholesterol  Levels  in  Children  (33). 
Estimation of relative abundance of proteins from reporter ion 
intensities  across  all  obtained  spectra  have  been  previously  de-
scribed (32). Linear mixed effects (LME) models were employed 
to estimate linear associations between each log2 transformed-
lipid or lipoprotein concentration as dependent variables and 
relative abundance of individual plasma proteins as a fixed effect, 
and each iTRAQ experiment as a random effect. Lipid values be-
low the lower limit of detection were excluded from these analy-
ses. We also adjusted for fasting status of children in all statistical 
models, as more than one-third of the children in the study were 




relative abundance of a protein, P value calculated by using a two-
sided test of a null hypothesis that there is no association between 
an individual protein and lipid or lipoprotein, q as FDR-adjusted 
P value to correct multiple comparisons (34), and r as a correla-
tion coefficient between measured plasma lipid or lipoprotein 





calculating pairwise protein:protein correlation coefficients for 
proteins quantified in relative abundance within each iTRAQ ex-
periment and averaged values across iTRAQ experiments.
Among proteins correlated with HDL-C, LDL-C, and triglycer-
ide concentrations, we estimated and compared mean differences 





z-scores less than 2, respectively, derived from the World Health 





descriptions of proteins were  extracted  from  the NCBI protein 
database, UniProt, and in-depth review of literature (39, 40). Data 
visualization was performed using the Cytoscape (41). The data-
sets of lipid profiles and relative abundance of reported proteins 
in this study are available in supplemental Table S2. All analyses 
were performed using the R Environment for Statistical Com-
puting  (version  3.1.2;  R  Foundation  for  Statistical  Computing, 
Vienna, Austria).
RESULTS
Lipid profiles and inflammation of children
In this cohort of 500 Nepalese children, median (inter-
quartile  range)  values of plasma  concentrations  for  total 
cholesterol, HDL-C, and LDL-C (n = 324) were 111 (100, 
127), 27 (21, 33), and 71 (62, 83) mg/dl, respectively, and 
89  (66,  118) mg/dl  for  triglycerides.  These medians  ap-
proximate plasma values less than fifth percentiles for total 
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cholesterol and HDL-C, less than tenth percentile for LDL-C, 
and greater than ninetieth percentile for triglycerides of dis-
tributions among child populations between the ages of 6 
and 9 in the United States (42, 43). The prevalence of high 





Child characteristics including lipid and lipoprotein profiles 
are compared by inflammation status in Table 1. Children 










observed in child demographic and educational character-
istics, economics of household, and dietary history between 
the two groups.
Plasma proteins correlated with LDL-C concentrations





Child Characteristics Inflammationa (n = 149) No Inflammationa (n = 351) Pb
Demographic
  Male, % 52.3 48.7 0.519
  Age, years 7.5 (0.4) 7.4 (0.4) 0.109
Ethnicity
  Pahadi (vs. Madheshi),c % 29.5 32.8 0.545
Anthropometryd
 Height, cm 113.6 (6.0) 114.1 (5.4) 0.372
 Weight, kg 18.0 (2.3) 18.4 (2.2) 0.209
  BMI, kg/m2 13.9 (1.0) 14.0 (1.0) 0.315
 Stunting,e % 47.7 35.5 0.015
 Underweight,e % 57.0 44.9 0.017
  Low BMI,e % 14.8 16.9 0.646
Education, %
 Ever sent to school 67.8 66.4 0.841
  Literacy 14.8 18.5 0.377
Economics of household, %
  Electricity 51.0 51.0 1.000
 Land ownership 77.2 76.9 1.000
Diet in the past 7 days (3 times),f %
  Bhat (rice) 98.9 100.0 0.451
 Corn and wheat 61.8 67.1 0.307
  Milk and curd 60.4 53.3 0.173
 Fish, chicken, and other meat 14.8 20.2 0.190
 Fruitg 40.3 39.9 1.000
  Dark green leafy vegetables 34.9 31.3 0.500
  Oil and ghyu (butter) 100 99.7 1.000
Morbidity in the past 7 days (1 time), %
 Fever 16.8 4.6 <0.001
 Diarrhea 7.4 1.4 0.001
 Productive cough 4.0 3.7 1.000
 Rapid breathing and grunting 3.4 2.6 0.846
Lipid or lipoprotein concentrationsh
  Total cholesterol, mg/dl 107 (100, 124) 112 (100, 128) 0.165
  HDL-C, mg/dl 25 (20, 31) 28 (22, 34) 0.005
  LDL-C, mg/dl 71 (64, 81) 72 (62, 83) 0.835
  Triglycerides, mg/dl 97 (69, 120) 87 (65, 114) 0.032
Inflammation was defined as plasma AGP concentration >1.0 g/l.
a Values are mean (SD), percentages, or median (interquartile range).
b P values were calculated using t-test for continuous variables with normal distributions, Mann-Whitney test for 
continuous variables with skewed distributions, and chi-square test for categorical variables.
c Pahadi pertains  to ethnic groups  that originated  in the Hills of Nepal; Madheshi pertains  to groups whose 
origin is the southern plains (Tarai) of Nepal.
d One outlier  in weight  (>45  kg)  and  two outliers  in height  (>140  cm)  and BMI  (>20 or  <10  kg/m2) were 
excluded.
e The z-scores were calculated based on the World Health Organization reference for 5–19 years (36). Stunting, 
height-for-age z-score less than 2;  underweight, weight-for-age  z-score  less  than 2;  and  low BMI, BMI-for-age 
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of  apoB. The  rest of  the proteins were mostly positive 
associates (r = 0.180.58; q = 3.74 × 102 to 4.41 × 107), 







Plasma proteins correlated with triglyceride concentrations
Three apoC proteins were most highly correlated with 
triglycerides (apoC-II/C-III/C-IV) (r = 0.510.54; q = 8.24 ×  
1013  to 7.22 × 1017)  (Table 3). Other positive  corre-
lates included cathelicidin antimicrobial peptide, pro-
teoglycan 4, retinol-binding protein 4 (RBP4), and apoE. 
Five negatively  associated proteins  included  extracellular 
matrix-related proteins, such as anthrax toxin receptor 
(ANTXR)2,  neuropilin  1,  and  insulin-like  growth  factor 
binding protein 1, and lipid transfer proteins such as CETP 
and phospholipid transfer protein (PLTP).
Plasma proteins correlated with HDL-C concentrations
Thirty-six proteins were positively correlated with HDL-C 
(Table 4). apoA-I (r = 0.79; q = 1.06 × 1091) and apoA-II 








velopmental  regulator  2  (IFRD2),  eukaryotic  translation 
initiation factor 2D (EIF2D), Kruppel-like factor 17 (KLF17), 
and TATA element modulatory  factor 1 (TMF1), were 
also  strongly  correlated with HDL-C.  Proteins mediating 
cell-cell and cell-extracellular matrix interaction, such 
TABLE  2.  Proteins correlated with plasma LDL-C concentrations in children of rural Nepal aged 6–8 years (n = 324)
Protein Name na r R2 P q
Percent 
Changeb Accessionc Referenced
apoB 324 0.69 0.48 6.39 × 1050 8.84 × 1047 120.8 105990532 (5, 13, 14, 53, 76–78)
Kinesin family member 20B (KIF20B) 208 0.47 0.22 6.38 × 1010 4.41 × 107 37.2 46049114
Platelet-activating factor acetylhydrolase (PAF-AH) 266 0.30 0.09 4.49 × 107 1.55 × 104 25.7 189095271 (5, 13)
G2/mitotic-specific cyclin B3 (CCNB3) 83 0.58 0.34 1.59 × 106 3.14 × 104 34.5 90669307
Zinc finger and BTB domain containing 1 (ZBTB1) 74 0.58 0.33 4.29 × 106 6.70 × 104 50.8 182509178
Netrin receptor UNC5C (UNC5C) 91 0.46 0.21 4.36 × 106 6.70 × 104 38.3 16933525
CETP, plasma 319 0.21 0.05 1.24 × 104 1.01 × 102 19.7 169636439
Proteoglycan 4 (PRG4) 260 0.23 0.05 2.50 × 104 1.79 × 102 27.0 189181724
Chondroadherin (CHAD) 86 0.42 0.18 4.61 × 104 2.77 × 102 23.4 153251229
Poly (ADP-ribose) glycohydrolase (PARG) 92 0.36 0.13 5.50 × 104 2.99 × 102 25.1 70610136









Protein Name na r R2 P q
Percent 
Changeb Accessionc Referenced
apoC-II 472 0.54 0.29 4.20 × 1020 7.22 × 1017 47.2 32130518 (5, 53)
apoC-III 472 0.53 0.29 3.31 × 1019 2.84 × 1016 48.8 4557323 (5, 15, 53)
apoC-IV 472 0.51 0.26 1.44 × 1015 8.24 × 1013 37.8 4502161 (5, 15, 53)
Cathelicidin antimicrobial peptide (CAMP) 394 0.44 0.19 1.18 × 106 5.07 × 104 25.1 39753970 (53)
Proteoglycan 4 (PRG4) 380 0.40 0.16 7.07 × 106 2.43 × 103 49.3 189181724
ANTXR2 346 0.40 0.16 1.85 × 105 5.28 × 103 28.3 50513243 (53)
CETP, plasma 465 0.40 0.16 2.33 × 105 5.71 × 103 23.9 169636439 (53)
Neuropilin 1 (NRP1) 432 0.39 0.15 5.14 × 105 1.10 × 102 25.4 66864913
RBP4 472 0.40 0.16 2.45 × 104 3.91 × 102 30.1 55743122
apoE 472 0.40 0.16 2.45 × 104 3.91 × 102 30.9 4557325 (53)
PLTP 445 0.39 0.15 2.73 × 104 3.91 × 102 27.9 5453914 (5, 15, 53)
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ANTXR1 and ANTXR2, were also among positive corre-
lates. Associated fat-soluble vitamin transporters included 
retinol  binding  protein  4,  transthyretin,  and  afamin. 




-2-glycoprotein  1)  and  the  complement  system  (i.e., 
complement  component  9  and  complement  factor  I). 
Protein-protein correlations as well as molecular network 
and functional clusters of the plasma HDL-C proteome are 
visualized in Fig. 1A and B. Prominent correlations among 
proteins positively  associated with HDL-C  (Fig.  1A) were 
found between apoA-I and apoA-II (r = 0.75, colored in 
orange) and apoA-I with other intracellular proteins, such 
as  IFRD2, EIF2D, KLF17, and TMF1 (r  = 0.530.91, col-
ored in blue). Among negative HDL-C correlates (Fig. 1B), 
proteins involved in the acute phase response proteolytic 
inhibition  were  strongly  correlated  with  each  other  (r  = 
0.360.90, colored in red). Correlates of HDL-C appear 
to be involved in a wide range of functions that extend 
beyond known functions of HDL, such as regulation of 
TABLE  4.  Proteins positively correlated with plasma HDL-C concentrations in children of rural Nepal aged 6–8 years (n = 464)
Protein Name na r R2 P q
Percent  
Changeb Accessionc Referenced
apoA-I 464 0.79 0.62 7.68 × 1095 1.06 × 1091 183.8 4557321 (7, 10–12, 60, 80–91)
IFRD2 450 0.64 0.41 3.59 × 1033 2.47 × 1030 63.9 197333755
apoA-II 464 0.58 0.34 9.04 × 1024 4.16 × 1021 76.9 4502149 (7, 10–12, 60, 80–85, 87–91)
apoD 464 0.56 0.31 8.22 × 1019 2.72 × 1016 53.2 4502163 (7, 12, 60, 80–85, 87–91)
EIF2D 238 0.57 0.33 9.85 × 1019 2.72 × 1016 61.0 56699485
apoC-I 464 0.51 0.26 1.44 × 1013 2.83 × 1011 18.6 4502157 (7, 10, 11, 60, 80–85, 87–91)
apoM 464 0.51 0.26 7.09 × 1013 1.22 × 1010 54.8 22091452 (7, 10–12, 60, 80–82, 84, 85, 
87–91)
PLTP 438 0.51 0.26 1.40 × 1010 2.15 × 108 50.3 5453914 (7, 60, 80, 81, 87, 88, 91)
ANTXR2 337 0.51 0.26 1.71 × 1010 2.36 × 108 42.8 50513243 (60)
TMF1 228 0.54 0.29 4.74 × 109 5.95 × 107 33.0 110347443
KLF17 258 0.50 0.25 6.99 × 109 8.04 × 107 26.4 104294874
PON1 464 0.49 0.24 8.81 × 109 9.35 × 107 27.3 19923106 (7, 11, 12, 60, 80–85, 87–91)
ANTXR1 315 0.45 0.21 2.39 × 107 2.36 × 105 30.0 14149904 (60)
SAA4 459 0.47 0.22 7.79 × 107 7.17 × 105 23.9 10835095 (7, 10, 60, 80, 81, 83–85, 87–91)
PON3 457 0.46 0.21 1.23 × 106 1.06 × 104 28.1 29788996 (7, 60, 80, 81, 88, 91)
BPI fold containing family B  
member 1 (BPIFB1)
189 0.52 0.27 1.91 × 106 1.55 × 104 26.6 40807482 (60)
apoF 464 0.47 0.22 3.96 × 106 3.03 × 104 24.9 4502165 (7, 60, 80–83, 85, 88–91)
Glycosylphosphatidylinositol specific  
phospholipase D1 (GPLD1)
464 0.46 0.21 9.82 × 106 6.73 × 104 31.6 29171717 (60, 80, 82)
Secretoglobin, family 3A member 1 
(SCGB3A1)
279 0.54 0.29 1.02 × 105 6.73 × 104 14.7 50363226 (91)
LCAT 464 0.45 0.20 2.94 × 105 1.69 × 103 52.3 4557892 (7, 60, 80, 87, 88, 91)
apoC-III 464 0.45 0.20 3.16 × 105 1.74 × 103 15.5 4557323 (7, 10–12, 60, 80–91)
RBP4 464 0.45 0.21 4.47 × 105 2.37 × 103 23.4 55743122 (7, 80, 82, 84, 85, 87, 88, 90)
CD99 molecule (CD99) 444 0.41 0.17 4.78 × 105 2.39 × 103 17.1 171543879
DNA repair and recombination  
protein RAD54B (RAD54B)
98 0.54 0.29 7.95 × 105 3.66 × 103 41.2 6912622
apoA-IV 464 0.45 0.20 9.49 × 105 4.23 × 103 18.4 71773110 (7, 10–12, 60, 80–91)
Transthyretin (TTR) 464 0.45 0.20 1.02 × 104 4.42 × 103 32.3 4507725 (7, 10–12, 80–82, 84–86, 88, 90, 
91)
Integrin 2 (ITGA2) 175 0.50 0.25 1.32 × 104 5.51 × 103 31.1 116295258 (60)
Exostosin-like glycosyltransferase  
2 (EXTL2)
301 0.45 0.21 2.10 × 104 7.82 × 103 21.0 14149609
Golgin B1 (GOLGB1) 322 0.44 0.20 2.28 × 104 8.28 × 103 19.5 148596984
Attractin (ATRN) 464 0.45 0.20 2.94 × 104 1.04 × 102 34.7 21450863
Heat shock 70 kDa protein 12A  
(HSPA12A)
107 0.47 0.22 6.29 × 104 2.01 × 102 43.2 119874213
Afamin (AFM) 464 0.44 0.19 7.23 × 104 2.17 × 102 21.2 4501987 (80, 82, 87, 90)
Sushi, von Willebrand factor type A,  
EGF and pentraxin domain-containing 
protein 1 (SVEP1)
69 0.61 0.37 7.86 × 104 2.31 × 102 46.4 148886654
Aldehyde dehydrogenase 9 family  
member A1 (ALDH9A1)
85 0.53 0.28 1.11 × 103 2.99 × 102 19.9 115387104
Suprabasin (SBSN) 121 0.53 0.28 1.88 × 103 4.42 × 102 39.5 38348366
Plexin domain-containing protein 1 
(PLXDC1)
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gene transcription and translation and extracellular matrix 
homeostasis.
Changes in relative abundance of proteins correlated 
with LDL-C, triglyceride, and HDL-C concentrations by 
inflammation status
The relative abundance of proteins associated with the 
investigated lipids and lipoproteins was compared in chil-
dren with inflammation (plasma AGP >1.0 g/l) to children 
without inflammation (AGP 1.0 g/l) (Fig. 2). Among 








teins  involved  in HDL biosynthesis  (i.e.,  LCAT),  vitamin 
transport (i.e., RBP4), protection against oxidative stress 
TABLE  5.  Proteins negatively correlated with plasma HDL-C concentrations in children of rural Nepal aged 6–8 years (n = 464)
Protein Name na r R2 P q
Percent 
Changeb Accessionc Referenced
Complement component 9 (C9) 464 0.45 0.20 1.28 × 105 7.59 × 104 20.7 4502511 (7, 60, 82, 87, 90)
Orosomucoid 1 (ORM1) 464 0.45 0.20 6.89 × 106 4.50 × 104 15.7 167857790 (80, 85, 87–91)
Galectin 10 (CLC) 377 0.48 0.23 3.85 × 105 2.09 × 103 7.0 20357559
Complement factor I (CFI) 464 0.44 0.20 1.92 × 104 6.96 × 103 25.3 119392081 (82, 87)
Leucine-rich -2-glycoprotein 1 (LRG1) 464 0.44 0.19 8.98 × 105 4.04 × 103 15.5 16418467 (80, 87)
Beta-2-microglobulin (B2M) 457 0.43 0.18 7.81 × 104 2.22 × 102 13.1 4757826 (80, 87, 88)
Fatty acid binding protein 12 (FABP12) 77 0.37 0.14 1.18 × 103 3.14 × 102 9.2 157427691
Thymidine phosphorylase (TYMP) 315 0.44 0.19 1.81 × 103 4.03 × 102 13.0 4503445
Tubulin tyrosine ligase-like family member 8 
(TTLL8)
272 0.33 0.11 2.15 × 104 7.40 × 103 19.3 122937293
TNFAIP3 interacting protein 1 (TNIP1) 356 0.45 0.20 8.82 × 104 2.45 × 102 13.6 116256481
Lysozyme (LYZ) 457 0.44 0.19 1.07 × 103 2.92 × 102 15.0 4557894 (84, 87)
Inter--trypsin inhibitor heavy chain family  
member 4 (ITIH4)
464 0.45 0.20 1.25 × 103 3.19 × 102 27.2 31542984 (7, 11, 60, 80, 82, 
86, 87)
Conserved oligomeric Golgi complex  
subunit 3 (COG3)
202 0.49 0.24 1.69 × 103 4.02 × 102 12.4 13899251
Heat shock 70 kDa protein 5 (glucose-regulated 
protein, 78 kDa) (HSPA5)
458 0.42 0.17 2.01 × 103 4.30 × 102 19.1 16507237
Thyroxine-binding globulin (SERPINA7) 464 0.44 0.19 1.70 × 103 4.02 × 102 19.5 205277441 (87)
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(i.e.,  PON1),  and  angiogenesis  and  tissue  repair  (i.e., 
ANTXR1 and ANTXR2), among others, were less abun-
dant  in  children  with  inflammation  than  those  without 
inflammation.  An  exception  was  SAA4,  an  apolipoprotein 
that was positively  correlated with HDL-C  (Table  4),  but 
also a positive acute phase reactant, that was 12% higher 
in  inflamed  children. Among LDL  and  triglyceride pro-
teomes,  relative  abundance  of  one  (apoM)  and  four 
proteins  (i.e.,  ANTXR2, RBP4,  apoC-III,  and  PLTP),  re-






South Asia, abnormal lipid and lipoprotein profiles were 
common in young school-aged children, characterized by 
elevated plasma  triglycerides,  low HDL-C concentrations, 
and  subclinical  inflammation. Our  untargeted  plasma 
proteomics approach revealed distinct distributions of 11, 
12,  and  52  plasma proteins  systemically  associated with 
LDL-C, triglyceride, and HDL-C concentrations, respec-
tively,  whose  functions  extend  beyond  canonical  lipid 
transport and metabolism. Inflammation was associated with 
remarkable differences in relative protein abundance, 
especially among biomarkers linked to HDL-C. These results 
collectively  suggest  that  the  family  of  plasma  proteomes 
correlated with circulating lipoprotein concentrations 





temic regulation of lipoprotein metabolism.
The proteome of LDL-C in Nepalese children reveals 
a unique protein composition dominated by apoB. The 
strong positive  correlation of  apoB with LDL-C  is  consis-
tent  with  evidence  that  apoB  accounts  for  about  95%  
of the total protein mass in a LDL particle (44). Among 
the  remaining proteins,  kinesin  family member 20B was  
the second strongest correlate of LDL-C, a motor protein 
known to transport intracellular vesicles along microtu-
bules (45). A previous study showed elevated levels of se-
rum cholesterol  in kinesin  family member 13B knockout 
mice, elucidating its novel role in the regulation of blood 
cholesterol  by  facilitating  endocytosis  of  cell  membrane 
receptor-binding LDL in hepatocytes (46). To our knowl-
edge,  this  is  the first  human  study  to  show  that  abun-
dance of the same kinesin family member in plasma is 
positively  correlated  with  plasma  LDL-C  concentrations, 













LDL  remodeling  from VLDL by  transferring  cholesteryl 
esters from HDL to VLDL particles in an exchange for 
triglyceride to HDL (50). LDL-C was also correlated with 
intracellular proteins involved in axon guidance (netrin 
receptor UNC5C),  control  of  cell  cycle  (cyclin  B3),  and 
DNA damage  response  (zinc  finger  and BTB  domain-
containing  protein  1),  although  their  tissue  origins  and 









timicrobial  peptide,  is  a  family  member  of  antibacterial 
and  lipopolysaccharide-binding proteins mostly  found  in 
neutrophil  and macrophage  granules  (51).  This  protein 
has been shown to complex with LDL/VLDL particles (52, 
53), suggesting that VLDL may serve as a plasma reservoir 
of  this  antimicrobial  protein.  Proteoglycan  4  correlated 
with both LDL-C and triglycerides in study children. Con-
sistent with our results, Geyer et al. (17) also reported that 
proteoglycan  4  was  the  second  most  strongly  correlated 
protein with both LDL-C and triglycerides, following apoB 
and  apoC-III,  respectively,  and  downregulated  by  weight 
loss in obese individuals. As proteoglycan 4 is a major adi-
pocyte extracellular matrix protein  (54),  it may occur  in 
plasma from tissue leakage.
The plasma HDL proteome comprised the highest num-
ber  of  proteins  reflecting  diverse  biological  functions  of 
HDL particles (8). Among 36 positive correlates of HDL-C 
concentrations, nine were apolipoproteins, including 
apoA-I. Accounting  for 70% of HDL protein,  apoA-I has 
been shown to confer anti-inflammatory, anti-oxidative, 
and cardioprotective properties to the lipoprotein com-
plex (2, 4). Less abundant apolipoproteins, such as apoA-II/
A-IV/C-I/C-III/D/F/M  and  SAA4,  are  also  known  to 
coregulate metabolism, including interactions with other 
lipoproteins and cell-specific receptors (1). PLTP is the pri-
mary protein that transfers phospholipids from triglyceride-
rich lipoproteins to HDL, representing the maturation 
of HDL particles (55). LCAT, the extracellular cholesterol-
esterifying enzyme, promotes efflux of cholesterol depots 





sistent with their known roles in HDL of transporting fat-
soluble vitamins A and E (29, 58).
Interestingly, our analysis has revealed several novel cor-
relations between HDL-C and its constituent apoA-1 with 
intracellular proteins (Fig. 1A). IFRD2 shared the second 
strongest correlation with HDL-C, although its general 
functions remain unknown. EIF2D, KLF17, and TMF1 are 
known to coregulate transcriptional and translational pro-
cesses. Although these proteins are not likely carried by 
lipoproteins and mechanisms giving rise to these strong 
correlations with HDL-C in plasma are unknown, we postu-
late that they may regulate expression of apoA-1 or other 





lular molecules and growth factors that promote resolution 
of inflammation and wound healing with epithelial prolif-
eration (62).





hosts a large number of acute phase reactants and com-




HDL is an integral component of the innate host defense 
system (6, 8).
In this thin pediatric population, elevated plasma triglyc-
erides and low concentrations of HDL-C were common. 












in the relative abundance of HDL-correlated proteins ap-








(72).  Reduced  PON1  (8%)  can  promote  oxidation  of 
LDL and lead to increased accumulation of cholesterol in 
macrophages  (73).  It  has  been  suggested  that  increased 
abundance of acute phase proteins residing in HDL parti-
cles are part of the innate response that provides rapid pro-
tection  to  a  host  (74).  However,  an  unresolved  chronic 
presence of  pro-inflammatory  agents with  loss  of  anti-
inflammatory and anti-oxidative proteins may compromise 
the atheroprotective capacity of HDL (74). Changes in the 










plasma  proteomes  of  lipoproteins  and  triglyceride  in  a 
population of undernourished children, often considered 
to be at low risk of dyslipidemia. Extensive data on nutri-
tional  status  and  subclinical  inflammation  enabled  us  to 
estimate the potential effects of inflammation on a fam-
ily of plasma proteomes correlated with lipid and lipo-
proteins. An unbiased quantitative plasma proteomics 
approach allowed us to discover a broadened scope of pro-
teomes by discovering novel proteins originating probably 
in the liver, peripheral tissues, vascular endothelium, and 
immune cells that may be interpreted to reflect population 
homeostasis  of  lipoproteins  and  their  likely  interactions 
with multiple tissues. A major limitation is that we were un-
able  to  differentiate  detected  proteins  by  whether  they 
were physically bound to lipoprotein particles because we 
did not isolate and purify lipoprotein particles by ultracen-
trifugation  (75).  Another  limitation  of  this  study  is  that 
high minimum detectable limits of lipid measurement re-
sulted in many missing values, especially in LDL-C con-
centrations. Lastly, due  to  the  relative  scale of protein 
abundance quantified by iTRAQ MS, absolute abundance 
of individual proteins could not be compared. As some 
identified proteins serve as indicators of both lipid status 
and  likely  cardioprotective  or  atherosclerotic  function, 
these proteins may be good candidates for targeted quanti-
fication and further evaluation.
In this generally undernourished population of school-
aged children living in the rural southern plains of Nepal, 
global plasma proteomic characterization revealed a family 
of lipoproteomes with distinct proteins correlated with 
concentrations of LDL-C  and  triglyceride,  and  a  large 
highly  diverse HDL  proteome  that  displayed  substantial 
variation  by  inflammation  status.  As  dyslipidemia  and 
chronic inflammation, both major risk factors of cardiovas-
cular disease, may also coexist among children in similar 
impoverished settings, further studies are warranted to 
evaluate clinical and public health implications of identi-
fied  proteins  as  early  childhood  biomarkers  of  vascular 
health and disease in later life.
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